CLINICAL ROLE -
Do Pharmacy Schools Provide Adequate OTC Training?
Mary M. Bridgeman, PharmD, BCPS, CGP, FASCP, clinical associate professor at the Ernesto Mario School of Pharmacy, Rutgers University, discusses whether pharmacy schools provide adequate OTC training.
Which Rx-to-OTC Switches Could Be on the Horizon?
Mary M. Bridgeman, PharmD, BCPS, CGP, FASCP, clinical associate professor at the Ernesto Mario School of Pharmacy, Rutgers University, discusses potential Rx-to-OTC switches.
High Cost Drug Launches in Specialty Pharmacy
Sheila Arquette, RPh, director of pharmacy services at Independent Health, discusses the lessons of high cost drugs such as PCSK9 inhibitors on specialty pharmacy.
Pharmacy Week in Review: May 5, 2017
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Treating Chronic Conditions in Specialty Pharmacy
Eric Peacock, CEO of MyHealthTeams, discusses effective treatment of patients with chronic conditions.
Staying Focused on Common Goals in Specialty Pharmacy
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses how the needs of specialty pharmacy, payers, and manufacturers can be aligned.
Factors That Could Impact Specialty Pharmacy Patients
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses high drug costs and the specialty pharmacy patient.
Enhanced Collaboration Among Specialty Stakeholders
Rinku A. Patel, PharmD, RPh, discusses how to improve communication among patients, physicians, pharmacists, and payers.
How Specialty Pharmacies Can Gain Access to Limited Distribution Drugs
Cheryl Allen, vice president of Industry Relations at Diplomat, discusses how specialty pharmacies can best position themselves to access limited distribution drugs.
Pharmacy Week in Review: April 28, 2017
ACO Growth and Specialty Pharmacies
Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses how specialty pharmacies will be impacted by the growth of accountable care organizations.
Access to Specialty Drugs Remains a Challenge
Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses how specialty pharmacies can help patients gain access to costly specialty drug regimens.
Novel Approaches in Improving HF Management
Biomarkers and Future Strategies in Heart Failure
Improving Inpatient to Outpatient HF Care Transitions
Switching HF Medications in the Inpatient Setting
Heart Failure Management: Updating Hospital Order Sets
Hospital Pharmacy Perspective: HF Medication Review
Acute Decompensated Heart Failure Hospitalization
The Role of Sacubitril/Valsartan in HFrEF
Angiotensin Receptor Neprilysin Inhibition in Heart Failure
The Role of Ivabradine in Heart Failure Management
Blocking the RAAS Pathway in Heart Failure
Heart Failure Pathways and the Role of Beta Blockers
The Usefulness of Measuring BNP Levels in Heart Failure
Characteristics of Patients with HFrEF
The Underappreciated Burden of Heart Failure
Streamlining Relationships Among Specialty Pharmacy Stakeholders
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses how communication can be improved among specialty pharmacies, manufacturers, and pharmacy benefit managers.
Biosimilars in Specialty Pharmacy
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses the potential impact of biosimilars on specialty pharmacy.
Optimal Management Programs Vital to Specialty Patient Success
Rebekah L. Hanson, PharmD, BCPS, BCACP, discusses the elements of an effective patient management program in specialty pharmacy.
